Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
A phase II, double blind randomized study to evaluate the immunogenicity of the therapeutic HIV-1 vaccine NYVAC-B versus placebo in chronic HIV-1 infected patients successfully treated with HAART (TheraVac-03)

Proposed period of release:
01/09/2008 to 01/04/2010

Name of the Institute(s) or Company(ies)
Academic Medical Center, Amsterdam;

3. Is the same GMO release planned elsewhere in the Community?
Germany; France;

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Poxviridae, Subfamily: Chordapoxviridae, Genus: Orthopoxviruses, species: Vaccinia, strain: NYVAC (New York Vaccinia Virus)

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar

Final report

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known